Select Sidearea

Populate the sidearea with useful widgets. It’s simple to add images, categories, latest post, social media icon links, tag clouds, and more.

SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002 for Psoriasis

SFA Therapeutics will begin testing of SFA001 in a Phase 1 exploratory trial at Einstein Hospital in Philadelphia 1Q 2023

Dr Manisha Verma MD, MPH to act as principal investigator

SFA Therapeutics to test its novel anti-inflamaatory compound, SFA001 in NASH patients. SFA001 is a powerful microbiome derived orally active small molecule has been shown to greatly reduce chronic inflammation. Chronic inflammation leads to the activation of hepatic stellate cells that undergo trans-differentiation to become myofibroblasts, the main extra-cellular matrix producing cells in the liver; over time increased extra-cellular matrix production results in the formation of liver fibrosis. The study will explore the ability of SFA001 to reduce fibrosis in patients.